Elite Pharmaceuticals, Inc. (ELTP)
OTCMKTS · Delayed Price · Currency is USD
0.28885
+0.00085 (0.30%)
At close: Aug 28, 2026
Elite Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 141.01 | 148.87 | 84.04 | 56.63 | 34.16 | 32.26 | |
Revenue Growth | 33.72% | 77.13% | 48.42% | 65.79% | 5.87% | 27.11% |
Cost of Revenue | 79.71 | 73.85 | 43.96 | 30.27 | 17.56 | 17.47 |
Gross Profit | 61.31 | 75.02 | 40.09 | 26.36 | 16.59 | 14.8 |
Selling, General & Admin | 17.74 | 17.6 | 9 | 7.15 | 5.12 | 4.46 |
Research & Development | 6.1 | 5.74 | 7.96 | 6.88 | 6.2 | 4.05 |
Operating Expenses | 25.52 | 25.06 | 18.88 | 15.57 | 12.63 | 9.72 |
Operating Income | 35.79 | 49.96 | 21.2 | 10.79 | 3.97 | 5.07 |
Interest Expense | -0.31 | -0.4 | -0.77 | -0.59 | -1.11 | -0.19 |
Interest & Investment Income | 0.37 | 0.21 | 0.02 | 0.02 | 0.01 | 0 |
Other Non Operating Income (Expenses) | 30.09 | 7.89 | -18.9 | -11.52 | 0.42 | 1.43 |
EBT Excluding Unusual Items | 65.94 | 57.66 | 1.55 | -1.3 | 3.28 | 6.3 |
Gain (Loss) on Sale of Assets | - | - | - | - | 1 | - |
Asset Writedown | -0.85 | -0.85 | -1.6 | - | -0.29 | - |
Other Unusual Items | - | - | - | 1.76 | - | 0.86 |
Pretax Income | 65.1 | 56.81 | -0.05 | 0.46 | 3.99 | 7.16 |
Income Tax Expense | 8.43 | 11.94 | 4.26 | -19.65 | 0.42 | -1.74 |
Net Income | 56.67 | 44.87 | -4.31 | 20.11 | 3.56 | 8.9 |
Net Income to Common | 56.67 | 44.87 | -4.31 | 20.11 | 3.56 | 8.9 |
Net Income Growth | - | - | - | 464.56% | -59.97% | 74.87% |
Shares Outstanding (Basic) | 1,075 | 1,073 | 1,068 | 1,015 | 1,013 | 1,011 |
Shares Outstanding (Diluted) | 1,153 | 1,138 | 1,068 | 1,023 | 1,013 | 1,011 |
Shares Change | 7.97% | 6.56% | 4.40% | 1.02% | 0.23% | 7.17% |
EPS (Basic) | 0.05 | 0.04 | -0.00 | 0.02 | 0.00 | 0.01 |
EPS (Diluted) | 0.04 | 0.03 | -0.00 | 0.02 | 0.00 | 0.01 |
EPS Growth | - | - | - | 537.54% | -57.99% | 81.05% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 17.53 | 22.82 | 5.83 | -4.04 | -2.4 | 6.01 |
Free Cash Flow Per Share | 0.01 | 0.02 | 0.01 | -0.00 | -0.00 | 0.01 |
Gross Margin | 43.48% | 50.40% | 47.70% | 46.55% | 48.58% | 45.86% |
Operating Margin | 25.38% | 33.56% | 25.23% | 19.05% | 11.62% | 15.72% |
Profit Margin | 40.19% | 30.14% | -5.13% | 35.51% | 10.43% | 27.58% |
Free Cash Flow Margin | 12.43% | 15.33% | 6.94% | -7.14% | -7.02% | 18.63% |
EBITDA | 37.31 | 51.51 | 22.89 | 12.16 | 5.23 | 6.27 |
EBITDA Margin | 26.46% | 34.60% | 27.24% | 21.47% | 15.32% | 19.42% |
D&A For EBITDA | 1.52 | 1.55 | 1.69 | 1.37 | 1.26 | 1.19 |
EBIT | 35.79 | 49.96 | 21.2 | 10.79 | 3.97 | 5.07 |
EBIT Margin | 25.38% | 33.56% | 25.23% | 19.05% | 11.62% | 15.72% |
Effective Tax Rate | 12.95% | 21.02% | - | - | 10.64% | - |
Revenue as Reported | 148.87 | 148.87 | 84.04 | 56.63 | 34.16 | 32.26 |